MOL 43398 4
The polyglutamine/CAG disorders comprise a group of neurodegenerative diseases that are associated with polyglutamine (polyQ) expansion mutations in the respective disease genes that are otherwise unrelated (Cummings and Zoghbi, 2000) . Abnormally long polyQ stretches cause proteins to misfold and produce intracellular protein aggregates. It is thought that polyQ aggregation follows a stochastic nucleation dependent process that initiates oligomerisation, amyloid-like fibril formation and the production of structures called inclusion bodies (IBs) (Perutz and Windle, 2001) . Because polyQ misfolding/aggregation is associated with cellular toxicity (Ross and Poirier, 2004) , it is crucial to understand the cellular mechanisms that control misfolding/aggregation with a view to the development of drugs that modify these pathways and alleviate disease.
The accumulation of intracellular IBs points to the inability of cells to dispose of mutant polyQ proteins using chaperone-assisted refolding (Muchowski and Wacker, 2005) and proteasome-mediated degradation (reviewed in Jana and Nukina, 2003) . Deciphering the mechanisms of degradation and clearance of polyQ expanded proteins, and how such mechanisms might be targeted using drugs, is a major focus of current research. Macroautophagy (here referred to as autophagy) is a process alternative to that of proteasomal degradation by which some long-lived proteins and organelles are cleared (Shintani and Klionsky, 2004) . Autophagy may be responsible for clearing polyQ expanded proteins and their assemblies (reviewed in Rubinsztein 2006) . Clearance by autophagy occurs by sequestration of the target organelle/protein into double membrane structures called autophagosomes that fuse with endo/lysosomes and discharge their contents, which are subsequently degraded. The mammalian homologue of Atg8 MAP-LC3 (LC3), is a key mediator of autophagy: after LC3 is C-terminally cleaved (LC3 I) phosphatidylethanolamine is added to the C-terminal glycine by the Atg5/12 complex, generating LC3 II bound to the nascent autophagosomal membrane (reviewed in Tanida et al. 2004b) .
Because the Atg5/12 complex catalytically activates the lipidation of LC3, trace amounts of Atg5 can support substantial autophagy whereas Atg5 knockout cells are totally deficient in autophagy (Hosokawa et al., 2006) . The hallmark of autophagic activation is the formation of autophagosome puncta containing LC3 II, while the biochemical measurement of autophagic activity is expressed as the amount of LC3 II that accumulates in the absence or presence of lysosomal activity.
Autophagy was first implicated in the regulation of IB formation and clearance of aggregateprone proteins based on use of chemical activators/inhibitors including the pro-autophagic drug rapamycin and knockdown of different autophagic genes (see Rubinsztein, 2006 and references therein).
The finding that rapamycin and its analogue CCI-779 protect against neurodegeneration in animal
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Molecular Pharmacology Fast Forward. Published on January 16, 2008 as DOI: 10.1124 at ASPET Journals on June 21, 2017 molpharm.aspetjournals.org Downloaded from models of misfolding diseases (Ravikumar et al., 2004; Berger et al., 2006) opens up immense hopes for treating debilitating diseases such as the polyQ disorders. Rapamycin, a macrolytic lactone produced by Streptomyces hygroscopicus, has immunosuppressive, antimicrobial, and antitumor properties. It binds intracellularly to FK506 binding protein 12 and targets the protein kinase mTOR (mammalian target of rapamycin). Inhibition of phosphorylation of mTOR by rapamycin activates autophagy and it has been suggested that rapamycin (or analogues) ameliorates neurodegenerative proteinopathies via activation of autophagy (reviewed in Rubinsztein, 2006) . However, mTOR impacts on various downstream targets not necessarily involved in autophagy, including the control of protein synthesis (reviewed in Dann and Thomas, 2006; Wullschleger et al., 2006) and because of these effects it is currently being evaluated in several Phase II clinical trials for cancer (reviewed in Sabbatini, 2006) . It is therefore unclear whether rapamycin mediates its protective effects solely via autophagy.
In order to probe the actions of rapamycin on the formation and clearance of expanded polyQ proteins and IBs we have taken advantage of clonal cell lines of autophagy proficient (Atg5+/+) and deficient (Atg5-/-) mouse embryonic fibroblasts (MEFs) that are easily amenable to biochemical and genetic rescue experiments. Using exon 1 of human htt containing 97 glutamines and fused to EGFP (Ex1HttQ97-EGFP) as an aggregation prone model polypeptide, we show that autophagy deficient cells accumulate insoluble Ex1HttQ97-EGFP more rapidly and form greater numbers of IBs compared to autophagy proficient cells. Re-expression of Atg5 in Atg5 deficient cells reversed this phenotype. Most strikingly, rapamycin reduced the amount of insoluble Ex1HttQ97-EGFP and IBs to a similar degree in both Atg5+/+ and Atg5-/-cells. The formation of SDS-insoluble polyQ assemblies is a cooperative process that is highly dependent on the accumulation of a critical mass of the protein Colby et al., 2006) . We suggest that a major effect of rapamycin is the reduction in protein synthesis required for polyQ aggregation and IB formation to occur.
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Expression vectors. Mammalian expression vectors encoding exon 1 of the HD gene with 25 or 97 glutamines fused at the C-terminus to a EGFP tag were a gift from Erich Schweitzer and Alan Tobin (Brain Research Institute, University of California, Los Angeles, CA 90095, USA). The mouse Atg5 expression vector and adenovirus mRFP-LC3 have been described previously (Mizushima et al., 2001; Bampton et al., 2005) .
Cell culture, transfection, inclusion load measurement and microscopy. SV-40 transformed MEF from Atg5+/+ and Atg5-/-mice (Kuma et al., 2004) were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Gibco) containing 10% foetal bovine serum (FBS; Sigma), 4.5 g/L Glucose, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma) in 5% CO2 at 37˚C. Cells were propagated in 75 cm 2 flasks and seeded on 12 mm poly-L-lysine coated glass cover slips in 24-well plates for fluorescence analysis or directly onto 6-well plates for immunoblot/filter-trap analysis. Cells were trypsinised, counted and seeded at a density of 4 x 10 4 cells per well in 24-well plates and 3 x 10 5 cells per well in 6-well plates. After an overnight culture, cells reached 60-80% confluence and were transiently transfected using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. The transfection medium was replaced with fresh medium after 4 h and cultures were incubated for a further 20 h in the presence or absence of the following inhibitors: 200 nM rapamycin (Rap; Sigma), 50 nM bafilomycin A1 (BafA1; Sigma), 0.3 to 0.01 µg/ml cycloheximide (CHX; Sigma). Cultures requiring longer time-courses were split 24 hours after transfection and re-seeded at lower densities for harvesting after 48 to 96 hours. Cells were fixed in 4% paraformaldehyde, washed in PBS, and analysed using epifluorescence microscopy with an Olympus X-170 microscope. Images were collected using an AstraCam camera and UltraView™ software (PerkinElmer). Inclusion load was calculated as the proportion of EGFP-expressing cells that contained inclusion bodies (IBs). At least 200 cells were counted per condition.
trichloroacetic acid, and after 3 washes with 5% trichloroacetic acid, the precipitate was dissolved in 15% SDS and radioactivity was measured by scintillation counting. Little tRNA was found in these pellets. Cells were counted after trypsinisation using a haemocytometer.
Immunoblotting, immunocytochemistry, filter trap assay, and re-solubilisation with formic acid.
Cells were either collected with a cell scraper, or trypsinised and counted using a haemocytometer before being pelleted and washed in phosphate buffered saline (PBS). Material was prepared for immunoblotting and filter-trap detection according to Wanker et al. (1999) . Briefly, cells were lysed on ice for 30 minutes in filter-trap lysis buffer (50 mM Tris-HCl, pH 8.8, 100 mM NaCl, 5 mM MgCl2 0.5% (w/v) NP-40, 1 mM EDTA) in the presence of Complete™ protease inhibitors (Roche). Insoluble material was pelleted by centrifugation at 16,000 x g for 10 min and resuspended in 100 µl DNaseI buffer (20 mM Tris-HCl, 15 mM MgCl 2 , 0.5 mg/ml DNase I (Sigma)) for 2 h at 37˚C. Protein concentrations of soluble (supernatant fraction) and insoluble fractions (pellet) were determined using the Bicinchoninic acid kit (Sigma) and BSA standards. Between 5 and 30 µg of insoluble material was diluted into 200 µl 2% SDS, boiled for 5 min, and applied to a 96-well dot blot apparatus (BioRad) containing a cellulose acetate membrane with 0.2 µm pore-size (Macherey-Nagel). Resolubilisation of pellets with formic acid was performed according to Hazeki et al. (2000) . Pellets were treated in 100 µl 100% formic acid for 1 hour at 37˚C, vacuum centrifuged and solubilised in 1x SDS PAGE sample buffer (see below). Soluble material was supplemented with 4x SDS-PAGE sample buffer (1 M TrisHCl pH 6.8, 400 mM DTT, 8% SDS, 40% glycerol) and 30 µg was used for analysis by SDS-PAGE (8% to 12.5%). Membranes were blocked in 5% milk for 1 hour and probed with the following primary antibodies: mouse monoclonal anti-GFP (8371-1, BD Biosciences at 1:4000, rabbit polyclonal antiphospho-S6 (2211, Cell Signalling) at 1:1000, mouse monoclonal anti-ERK (M12320, Transduction laboratories) at 1:5000, rabbit polyclonal anti-actin (A2066, Sigma) at 1:1000, mouse anti-vimentin (V6630, Sigma, 1:40). ICC was performed as in Bampton et al. (2005) . Rabbit polyclonal anti-LC3
antibodies were gifts from Yasuo Uchiyama (Osaka University Graduate School of Medicine, Osaka 565-0871, Japan and Eiki Kominami (Juntendo University School of Medicine, Tokyo, 113-8421 Japan). Rabbit polyclonal anti-Atg5 antibody was described previously (Mizushima et al., 2001) . Blots were subsequently probed with HRP-conjugated anti-mouse or anti-rabbit IgG (Jackson Immunoresearch Laboratories) at 1:5000 and visualised with ECL detection reagents (Amersham).
Immunoblots and dot blot signals were scanned with a flat bed scanner (hp scanjet 5470c, Hewlett
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RESULTS

Genetic ablation of Atg5 increases Ex1HttQ97-EGFP accumulation and inclusion body formation.
We first tested whether the complete genetic ablation of autophagy (Atg5) (Fig. 1) . However, cytoplasmic or nuclear
IBs were readily formed in Ex1HttQ97-EGFP-expressing cells of both types (Fig. 1 ). Evidence that Atg5+/+ MEFs were proficient to undergo autophagy whilst Atg5-/-MEFs were not was obtained by expression of mRFP-LC3. Fig. 1 shows that Atg5+/+ MEFs contained several mRFP-LC3 puncta while mRFP-LC3 expression in Atg5-/-MEFs was evenly diffuse, as shown previously (Bampton et al., 2005) . We did not observe co-localisation of mRFP-LC3 with IBs in wt cells at this time point (24 h).
The proportion of EGFP-expressing cells containing IBs increased over time in both cell types ( Fig. 2A) . About twice as many Ex1HttQ97-EGFP-positive Atg5-/-MEFs contained IBs compared to Atg5+/+ MEFs after 1-2 days ( Fig. 2A) . Nuclear inclusions in ca. 10-15% of both types of cells were evident from the fact that nuclear DNA was "vacated" from spots where the IBs had deposited (Fig. 1, arrows) (for quantification see Fig. 4 ). There was no difference in the transfection rate between Atg5-/-and Atg5+/+ cells (quantified in Fig. 4 ), transfection efficiency varying between 50-60% in both types of MEFs (see Supplementary Fig. S1 for low power fluorescent images of cells). It is important to note that at 24 h after transfection, we did not detect any differences in toxicity caused by either Ex1HttQ25-EGFP or Ex1HttQ97-EGFP expression in Atg5+/+ and Atg5-/-cells as assessed by inspection of nuclear abnormalities (ca. 5% of EGFP +ve cells showed baseline toxicity as measured by nuclear fragmentation; see Fig. 4 for a quantitative comparison). Therefore the increase in IB formation of Ex1HttQ97-EFP in Atg5-/-cells was neither due to unequal transfection nor to any differential toxicity due to IB formation in our experiments.
To test whether the increase in IBs in the Atg5-/-cells relative to Atg+/+ cells correlated with an increase in the accumulation of SDS-insoluble Ex1HttQ97-EGFP, we used the filter trap assay to measure the amount of SDS-insoluble Ex1Htt-Q97 protein formed in each cell type. Pellets remaining after protein extraction in 1% NP-40 were treated with DNase I, boiled in 2% SDS, and filtered onto a cellulose acetate filter using a dot blot apparatus while respective supernatant proteins were separated by SDS-PAGE. Fig. 2B shows that Ex1Htt-Q97 formed SDS-insoluble material in both types of MEFs while Ex1Htt-Q25 did not. Quantification showed that there was a two-fold increase of insoluble Ex1HttQ97-EGFP in Atg5-/-cells compared to Atg5+/+ cells hence correlating with increased IB formation in autophagy-deficient versus autophagy-proficient cells (Fig. 2D, filled bars, n=4, p<0.001).
To test for autophagic activity, we probed for LC3 by immunoblotting. Consistent with the lack of mRFP-LC3 puncta in Atg5-/-MEFs (Fig. 1B) , no LC3 II was detected in Atg5-/-extracts from Atg5-/-cells immunoblotted for LC3 but extracts from Atg5+/+ MEFs expressed LC3 II, the latter being the autophagosome-associated form of LC3. A similar amount of LC3 I was expressed in both cell types.
Equal input of soluble protein was confirmed with an antibody against ERK1 and 2 (tERKs). Further evidence for ongoing autophagy in Atg5+/+ cells was obtained by treatment with bafilomycin A1 (BafA1), which prevents LC3 II degradation in lysosomes and thus causes LC3 II to accumulate in autophagically-proficient cells (Kabeya et al., 2001; Bampton et al., 2005) . Figure shown) but without boiling, suggesting that no SDS-insoluble oligomeric Ex1HttQ97-EGFP species of more than 200 nm (pore size of filter) were generated.
We analysed whether the IBs are ubiquitinylated in both cell types as this is a hallmark of all polyQ diseases in vivo including HD. We found co-localisation of ubiquitin with IBs in ~5% of both Atg5+/+ and Atg5-/-cells ( Fig. 3 and data not shown). We also found that LAMP-1 (lysosome- 
Rapamycin reduces the amount of insoluble Ex1HttQ97-EGFP and inclusion body formation in both autophagy-proficient and -deficient cells
We next investigated whether rapamycin requires an Atg5-dependent mechanism to modulate the amount of insoluble Ex1HttQ97-EGFP and IB formation. MEFs were treated with 200 nM rapamycin either 12 h before transfection, to instil high autophagic activity prior to onset of polyQ expression and IB formation, or treated with rapamycin simultaneously with transfection. After 18-24 h, the percentage of EGFP-positive cells with IBs was determined while insoluble Ex1HttQ97-EGFP was measured using the filter trap assay as described above. To determine that rapamycin was active, we measured S6
phosphorylation. S6 is a ribosomal protein whose phosphorylation is regulated by S6 kinase in an mTOR-dependent manner (Nobukini and Thomas, 2004) . Fig. 4A shows that rapamycin added 12 h prior to transfection inhibited S6 phosphorylation in both cell types (transfected with Ex1HttQ25-EGFP or Ex1HttQ97-EGFP), indicating that rapamycin prevented mTOR activity independently of Atg5 activity. There was no difference in the amount of Ex1HttQ25-EGFP or Ex1HttQ97-EGFP expressed in either cell type treated with rapamycin compared to untreated cells when the total amount of soluble protein input was equalised between treatments, thus indicating that there is no differential destruction of the transfected proteins per se (Fig. 4A ).
Pre-treatment with rapamycin significantly decreased the proportion of EGFP-positive cells containing Ex1HttQ97-EGFP IBs by 40-45% in both Atg5+/+ and Atg5-/-MEFs (Fig. 4B ). To ensure that rapamycin treatment did not affect the transfection efficiency or toxicity of the Ex1Htt transgenes in either Atg5 cell type we monitored both. We and others have previously shown that analysis of nuclear morphology as measured by nuclear fragmentation and condensation using DNA stains is a reliable marker of cell toxicity under these conditions and strongly correlates with other markers of cell death (Wyttenbach et al., 2001) . Figure 4C shows that the toxicity associated with expression of Ex1HttQ25-or Q97-EGFP was at a baseline level (5%) under our experimental conditions (after 18-24 hours after
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 4B) was not due to a differential toxicity (mean ± SD, n=3, ANOVA p=0.6). To make sure that the differential increase in IBs between Atg5+/+ and Atg5-/-cells ( Fig. 2B and Fig. 4B ) and the decrease in IB formation by rapamycin was not due to unequal transfection rates, we measured the transfection under the various conditions by counting the number of EGFP positive cells in the total cell population after each experiment in parallel with the analysis of toxicity and IB. As shown in Figure 4D we obtained transfection efficiencies of 50-60%.
Importantly, neither the cell type nor rapamycin affected the rate of transfection (mean ± SD, n=3, ANOVA p=0.3). As we observed a minor proportion of IBs in the nuclear compartment ( Fig. 1) we also quantified the proportion of Atg5+/+ and Atg5-/-cells containing IB located in the nucleus versus cytoplasmic localisation and whether this distribution is modulated by rapamycin. Figure 4D shows that the 10-15% of nuclear IBs in both cell types was not changed under rapamycin treatment (mean ± SD, n=3, ANOVA p=0.9).
Having shown that rapamycin treatment reduced IBs in both cell types we next investigated whether this reduction was also observed in the amount of insoluble material. IBs are cellular structures (or aggresomes) that may not provide an adequate estimation of the amount of polyQ aggregation.
However, we measured a similar reduction in SDS-insoluble Ex1HttQ97-EGFP induced by rapamycin when this was assayed by filter trap, or after solubilising the SDS-insoluble pellet with formic acid, thereby controlling for equal protein input and loading between the different conditions ( Fig. 5A , quantified in B). There was no significant change in the amount of insoluble Ex1HttQ97-EGFP formed in cells that had been treated with rapamycin at the time of transfection compared to control (see supplementary Fig. S2 for raw data). Thus, rapamycin can decrease the amount of insoluble Ex1HttQ97-EGFP and IB load, but this effect occurs in an Atg5-independent manner, and with a considerable delay following its addition. Ravikumar et al (2004) found that mTOR was inactivated in polyQ-expressing cells, was bound to a polyQ expanded N-terminal portion of Htt and sequestered into IBs and thus suggested that autophagy is endemically activated in HD (and maybe other polyQ diseases) as a protective response. In
MEFs expressing Ex1HttQ97-EGFP, we failed to find an increase in mTOR immunoreactivity after solubilisation of IBs using formic acid. mTOR was also not trapped on the stacking gel in conjunction This article has not been copyedited and formatted. The final version may differ from this version. with Ex1HttQ97-EGFP (data not shown) so the degree of sequestration of mTOR may be cell-specific and time dependent.
Our finding that rapamycin reduced IBs and SDS-insoluble material in autophagy-deficient cells was unexpected. Hence we next investigated through which mechanism rapamycin reduced IBs and SDS-insoluble Ex1htt-Q97-EGFP. (Fig. 6A, third panel) . Thus, we conclude that rapamycin caused a significant reduction in protein per cell (p<0.001, t-test on pooled results, n=10 for each genotype).
Rapamycin reduces formation of insoluble
To test whether the reduction in total protein/cell due to rapamycin treatment included protein translated from Ex1htt expressing plasmid, we examined the amount of Ex1HttQ25-EGFP produced to avoid the uncertainty associated with the insolubility of Ex1HttQ97-EGFP (Ex1httQ25-EGFP is soluble
This article has not been copyedited and formatted. The final version may differ from this version. Met incorporation (Fig. 6D , first bar). This 39% reduction was almost identical to the reduction of 37 ± 3% found for total soluble protein (Fig. 6d , second bar) that we calculated in parallel in each of these experiments. Calculating the ratio of change in [ 35 S]methionine incorporation over the reduction of total protein content, this value was no different from zero indicating that the reduction in the global amount of protein (as shown in Fig. 6A and D) is likely to be due to an inhibition of protein synthesis.
Inhibition of protein synthesis by cycloheximide reduces the level of insoluble Ex1HttQ97 and inclusion body formation similar to rapamycin
To investigate how a decrease in protein synthesis per cell affects the propensity of cells to form insoluble Ex1HttQ97-EGFP and IBs, a concentration of cycloheximide (CHX), an inhibitor of protein synthesis, was sought that matches the decrease in the amount of soluble protein obtained with rapamycin. Cycloheximide was used because it binds to ribosomes reversibly thus ensuring a response that is proportional to ribosome occupancy over extended periods of treatment. In dose-response experiments using rapamycin, we did not observe a significant difference in the amount of reduction in global protein synthesis between 50-200 nM rapamycin (data not shown) and hence we aimed at a CHX concentration that would match that induced by 200 nM rapamycin.
As expected, the amounts of insoluble Ex1HttQ97-EGFP protein (Fig. 7A ) and IB formation ( (Fig. 7A) . The amount of IBs formed with rapamycin also closely matched that observed with this concentration range of CHX (Fig. 7B) , the amount of insoluble Ex1HttQ97-EGFP and IB formation being equally reduced. Moreover, steady state protein levels were reduced similarly by the same range of CHX and rapamycin (see Supplementary Fig. 5S ). Finally, when we compared the amount of [ (Fig. 7A) , suggesting that LC3 protein is being turned over quite quickly during this time by non-autophagic mechanisms.
Atg5 overexpression partially restores autophagic activity in Atg5-/-cells and reduces insoluble polyQ expanded Ex1Htt.
The characteristics of cell lines can diverge rapidly even when they derive from a common origin. To further investigate the role of autophagy in the control of insoluble Ex1HttQ97-EGFP and IB load, Atg5 was expressed in Atg5-/-and Atg5+/+ cells by transfection. Atg5 expression in Atg5-/-cells induced the formation of the Atg5/Atg12 conjugate and restored the ability of the cells to produce LC3 II to about 20% of the levels measured in Atg5+/+ cells (Fig. 8A) . Interestingly, we found co-localisation of overexpressed Atg5 with IBs (see Supplementary Fig. 4SA ) and a significant amount of Atg5 (but not Atg5/12 conjugate) accumulated in the pellets of both types of MEF cells expressing Ex1HttQ97-EGFP
( Supplementary Fig. 4SB shows results for Atg5-/-cells). Whether this Atg5 is disabled from performing its function (as no Atg12 accumulated in this fraction) remains to be resolved. Together these results suggest that some of the overexpressed Atg5 protein in Atg5-/-cells is functional, consistent with the recent finding of Hosokawa et al., (Hosokawa et al., 2006 ) using the same cell clone and DNA plasmids.
This article has not been copyedited and formatted. The final version may differ from this version. When the amount of insoluble material was examined using the filter trap assay (Fig. 8B) , overexpression of Atg5 in Atg5-/-cells reduced the amount of insoluble material that accumulated each day. Already after 1 day, the amount of insoluble Ex1HttQ97-EGFP in Atg5-/-cells expressing Atg5
decreased by 27 ± 8% compared to 2 ± 1% change in Atg5+/+ cells (mean ± SEM, n=4, p<0.02, t test; Fig. 8C ). To compare the rate of reduction of insoluble Ex1-Htt-Q97-EGFP under conditions of Atg5 overexpression over several days, we split and replated the transfected cells after 2 days of transfection and measured the rate of decrease of Ex1Htt-Q97-EGFP in both cell types (Fig. 8D ). Atg5 overexpression accelerated the reduction of Ex1Htt-Q97-EGFP in Atg5-/-cells, but not in Atg5+/+ cells. It is important to note that overexpression of Atg5 did not reduce the amount of total protein harvested from the Atg5-/-or Atg5+/+ cells (unlike rapamycin), suggesting that the decrease in Ex1HttQ97-EGFP caused by Atg5 is independent of protein synthesis (data not shown). Moreover, the number of cells harvested at each time point was similar between the four conditions, demonstrating that Atg5 overexpression had no effect on the cell cycle. It should be noted that insoluble Ex1Htt-Q97-EGFP also decreases over time in cells not overexpressing Atg5 from day 2-4 ( Fig. 8B, D) . This is likely due to continuous cell division, which reduces the number of plasmids present in each cell. A differential loss of cells containing insoluble Ex1Htt-Q97-EGFP between day 2-4 may also contribute to this finding. Together, these data show that re-expression of Atg5 in autophagy-deficient cells achieves a reduction in the amount of insoluble Ex1HttQ97-EGFP.
Discussion
In the present paper we show that autophagy-deficient cells lacking Atg5 expression accumulate more misfolded insoluble polyQ protein (Ex1HttQ97-EGFP) and form more inclusion bodies (IBs) than control cells and that this effect can be partially reversed by re-expressing Atg5. These data suggest that the lack of autophagy increases polyQ aggregation and/or reduces clearance of aggregation-prone polyQ proteins. Our results obtained through a genetic approach (complete genetic knockout of Atg5) are consistent with those of recent studies (Kouroku et al., 2006 , Iwata et al., 2005a Rapamycin is a well-characterised activator of autophagy and has previously been reported to alleviate toxicity of different aggregate-prone proteins (Rubinsztein, 2006) . In these reports the authors suggested that the beneficial effects of rapamycin resulted from its ability to reduce aggregation-prone toxic proteins via autophagy. Hence one would predict that rapamycin would reduce polyQ aggregation in autophagy-proficient cells, but not in autophagy-deficient cells. We tested this idea by treating This article has not been copyedited and formatted. The final version may differ from this version. It is likely that autophagy too can reduce polyQ aggregation not only through clearance of formed polyQ aggregates, but also by reducing the amount of polyQ protein submitted to these processes. These two mechanisms could be acting in an additive way. It is conceivable that some of the effects of rapamycin observed in previous studies may be due to a reduction in protein synthesis. In two studies where rapamycin was used during the period of Htt synthesis (Drosophila, transgenic mice) (Berger et al., 2006) , it was not reported whether there were changes in expression levels of the transgenes and hence it is possible that some of the protective effects were due to the inhibitory action of rapamycin on translation. However, a subtle reduction in the synthesis of an Htt fragment due to rapamycin may be difficult to detect in animal models. Rapamycin treatment has been proposed to inhibit translation of specific mRNAs rather than resulting in global inhibition of translation (Grolleau et al., 2002) . However, we found similar amounts of reduction in total protein per cell and in the amount of Ex1HttQ25-EGFP synthesised per cell, suggesting that there is no selectivity in nuclear versus plasmidbased CMV promoter mediated expression. At present, we cannot distinguish between a possible effect of rapamycin on global translation versus a more specific effect on a subset of mRNAs although it is clear that the function of some genes required for cell cycle are suppressed.
An interesting question is whether rapamycin mediates all its effects through mTOR. To date there are no known alternative targets of rapamycin other than FK506 binding protein 12, which inhibits the protein kinase mTOR (Wullschleger et al., 2006) , suggesting that the inhibitory effects of rapamycin on the synthesis (this study) and the clearance of aggregate prone proteins via autophagy (see Rubinstein, 2006 ) occur via mTOR. However, not all the effects of mTOR are mediated by autophagy.
The serine/threonine kinase mTOR is a highly conserved integrator of mitogenic and nutrient inputs and controls cell proliferation, cell growth and endocytosis. These activities are likely mediated through modulation of protein synthesis (Dann and Thomas, 2006; Wullschleger et al., 2006) , consistent with our observation of a reduction in insoluble Ex1httQ97-EGFP and IBs in the autophagy-deficient Atg5-/-MEFs. The extent of inhibition of protein synthesis of about 17% we observe is in keeping with the reported decrease of 15-50% in translation rates induced by mTOR inhibition in mammalian cells (whereas in yeast, inhibition is nearer 100%) (Jefferies et al., 1994; Terada et al., 1994) . Hence, it is likely that the effect of rapamycin on protein synthesis is cell type dependent. It remains to be seen to what extent this drug affects protein synthesis in neurons.
The reduction in insoluble Ex1HttQ97-EGFP achieved with rapamycin was mimicked by use of CHX. Several reports have demonstrated that CHX inhibits autophagy (Kovacs and Seglen, 1981) by
This article has not been copyedited and formatted. The final version may differ from this version. preventing fusion of autophagosome with endo/lysosomes (Lawrence and Brown, 1993) . Consistent with this view, IBs were cleared more quickly in the presence of rapamycin in an inducible cell model after expanded httEx1 protein synthesis was turned off but IBs appeared to accumulate when CHX (10 µg/ml) was present with rapamycin (Ravikumar et al., 2002 ). In the above papers 2-10 µg/ml CHX was used, which inhibits protein synthesis and autophagy over 95% whereas in our study, the concentration that mimicked rapamycin's effect was between 0.01-0.03 µg/ml, which elicited only a partial block on protein synthesis and presumably on autophagy. However, our important observation is that the same reduction in insoluble material and IBs were elicited by CHX in Atg5-/-MEFs, where no autophagy can take place. Hence the phenomenon we observed here is unlikely to be related to autophagy.
Autophagic clearance of Htt fragments may be promoted independently of mTOR (and S6K/Akt) via a pathway dependent on insulin receptor substrate 2 (IRS2) and stimulated via insulin and IGF-1 (Yamamoto et al., 2006) . The notion that there are mTOR-independent pathways of autophagy is suggested by the finding that rapamycin inhibited autophagy suppression by insulin but not by regulatory amino acids in liver cells (Kanazawa et al., 2004) and yeast susceptibility to osmotic stress differed when induction of autophagy was by starvation or rapamycin (Prick et al., 2006) . Indeed, it has recently been shown that small-molecule enhancers of mammalian target of rapamycin (mTOR) can act independently of rapamycin to enhance clearance of mutant huntingtin fragments and A53T alphasynuclein (Sarkar et al., 2007) . These findings suggest that multiple mechanisms may regulate autophagic clearance of misfolded/aggregated proteins. However, irrespective of how the proteins are cleared, a reduction in the critical mass of aggregation-prone proteins such as that described in the present study will always be beneficial in reducing protein aggregation.
Reducing the expression of Htt is in theory a promising strategy to alleviate disease: a decrease in expression of wildtype Htt up to 50% is not detrimental (based on studies in heterzygotes) while decreasing the expression of mutant Htt using an siRNA approach has been found to significantly reduce HD pathology in mice (Wang et al., 2005; Machida et al., 2006) . This idea is supported by the recent findings of Colby et al (Colby et al., 2006) who proposed that an efficient therapeutic strategy for HD lies in reducing the rate of mutant Ex1Htt aggregation by only modestly reducing Htt expression levels. From our study we cannot conclude however that rapamycin would have a beneficial effect by reducing htt synthesis in all cases. Future in vivo studies will be required to address this point.
It is important to note that in HD in vivo, mutant Htt is constantly produced, hence the mechanisms by which rapamycin regulates the accumulation and turn-over of mutant Htt should be This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
